Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis.
Khawaja M TalhaJennifer GreenGerasimos FilippatosStuart PocockFaiez ZannadMartina BrueckmannElke SchuelerAnne Pernille OfstadJoao Pedro FerreiraStefan D AnkerJaved ButlerJulio RosenstockMilton PackerPublished in: Diabetes, obesity & metabolism (2024)
Empagliflozin exerts a consistent benefit on cardiovascular outcomes and renal function decline, irrespective of baseline insulin use, and reduces the need for sustained insulin initiation in patients with HF and diabetes.